Table 3: Multivariate linear regression: covariates associated with each outcome variablea assessed from baseline through 12 months.

Outcome variable b Independent variableLikelihood ratio c Parameter estimateStd. errort valuePr(>t)

CRPAndroidal fat mass90.690.0520.00524.50≤0.0001
FibrinogenAndroidal fat mass31.630.0120.0044.32≤0.0001
TLMP × Site0.1590.0513.120.0021
Positive Fam Hist0.2040.1121.820.070
InsulinAndroidal fat mass51.160.1430.0245.95≤0.0001
Time point 122.0130.6503.10.0022
HOMAAndroidal fat mass43.730.0120.0026.88≤0.0001
Time point 120.0110.0043.440.0007

a The number of observations included in the analysis varied depending on the outcome: 𝑁 = 2 1 7 for CRP and Hcy, 𝑁 = 2 1 8 for fibrinogen, insulin, and HOMA. The Hcy model was not statistically significant and thus not shown in this table.
b Each final longitudinal model included these obligatory variables: treatment (control versus combined treatment with 80 mg or 120 mg of isoflavones), time point (baseline versus 12, 24, or 36 months), treatment by time point interaction, and site (ISU versus UCD), as well as potential covariates that included androidal fat mass (kg) adjusted for height, time since last menstrual period (TLMP), family history of CVD (FamHx) coded as a categorical variable (none versus positive or none versus unknown), and Healthy Eating Index (HEI) score. The fibrinogen model included TLMP by site interaction. The insulin model (but not other models) included glucose as a covariate. This table shows only those covariates that were significant ( 𝑃 . 0 5 ) for each outcome variable or had a tendency ( 𝑃 . 1 0 ) to be significant.
c The likelihood ratio for each model represents the ratio of a model that includes only obligatory variables compared to the final model that includes obligatory variables and covariates. The overall P-value for each model was ≤.0001.